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Abstract
Background
Furosemide is the most common loop diuretic used worldwide. The off-label administration
of furosemide bolus(es) for the prevention or to reverse acute kidney injury (AKI) is wide-
spread but not supported by available evidence. We conducted a meta-analysis of random-
ized trials (RCTs) to investigate whether bolus furosemide to prevent or treat AKI is
detrimental on patients’ survival.
Methods
Electronic databases were searched through October 2017 for RCTs comparing bolus furo-
semide administration versus any comparator in patients with or at risk for AKI. The primary
endpoint was all-cause longest follow-up mortality. Secondary endpoints included new or
worsening AKI, receipt of renal replacement therapy, length of hospital stay, and peak
serum creatinine after randomization.
Results
A total of 28 studies randomizing 3,228 patients were included in the analysis. We found no
difference in mortality between the two groups (143/892 [16%] in the furosemide group ver-
sus 141/881 [16%] in the control group; odds ratio [OR], 0.84; 95% confidence interval [CI],
0.63 to 1.13; p = 0.25). No significant differences in secondary outcomes were found. A sig-
nificant improvement in survival was found in the subgroup of patients receiving furosemide
bolus(es) as a preventive measure (43/613 [7.0%] versus 67/619 [10.8%], OR 0.62; 95%
CI, 0.41 to 0.94; p = 0.03)
Conclusions
Intermittent furosemide administration is not associated with an increased mortality in
patients with or at risk for AKI, although it may reduce mortality when used as a preventive
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measure. Future high-quality RCTs are needed to define the role of loop diuretics in AKI pre-
vention and management.
Trial registration
The study protocol was registered on PROSPERO database for systematic reviews (Regis-
tration no. CRD42017078607 – http://www.crd.york.ac.uk/PROSPERO/display_record.
php?ID=CRD42017078607).
Introduction
Acute kidney injury (AKI) is a common complication in hospitalized patients, with an overall
estimated incidence of around 10%, increasing up to 60% among critically ill patients admitted
to an intensive care unit (ICU) [1]. Of these, 6% develop severe AKI, with approximately 70%
receiving acute renal replacement therapy (RRT)[2]. A relationship between renal failure and
increased short- and long-term morbidity and mortality is well recognized across several clini-
cal settings [1,3].
Currently, there are few interventions or medications that can alter the clinical course of
AKI and favorably modify the outcome of critically ill patients once AKI occurred [4,5].
The use of loop diuretics in critically ill patients with AKI is a long standing and widespread
clinical practice [6]. The rationale for the use of loop diuretics includes many aspects of their
action, including an increase of tubular flow, a reduction in oxygen consumption and ischemic
injury, and a reduction of TNF-induced apoptosis [7,8,9].
Furosemide remains the most common loop diuretic prescribed in critically ill patients
[6,10,11]. Experimental studies have suggested that the infusion of low doses of furosemide
can reduce the apoptosis phenomena induced by ischemia/reperfusion and gene transcription
associated therewith [12,13].
On one hand, some small studies have suggested that diuretics can reduce the severity of
acute renal failure transforming it from oliguric to not oliguric, reducing the duration of AKI,
improving the speed of recovery of renal function and probably reducing the need of renal
replacement treatment [14,15,16,17]. Furthermore, furosemide may also be helpful in the
management of volume overload and electrolyte homeostasis, which could be ultimately
related to AKI outcome [18,19].
On the other hand, several observational studies suggested that the use of diuretics in criti-
cally ill patients with AKI might not be associated with improvement in clinically relevant out-
comes, and may even increase mortality [10,11]. A possible detrimental effect of loops
diuretics administration has been suggested also for heart failure patients [20]. In addition,
some in vitro studies, where blood mononuclear cells were stimulated with lipopolysaccharide,
have revealed that high concentrations of furosemide could have cytotoxic and immunosup-
pressive effects characterized by reduced expression of interleukin-6, interleukin-8, and tumor
necrosis factor-alpha [21].
In clinical practice, it is common experience that intermittent (bolus) furosemide adminis-
tration is frequently the first strategy applied by clinicians when facing patients with early AKI,
especially when oligo-anuria is present. However, such strategy is not currently supported by
evidence-based medicine, and, in some settings, has been associated with harm [22,23].
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Thus, we decided to carry out a systematic review and meta-analysis of all randomized clin-
ical trials ever performed on furosemide bolus versus any comparator in any clinical AKI set-
ting to evaluate its effect on survival and on clinically relevant outcomes.
Methods
This study is a systematic review and meta-analysis conducted in keeping with Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [24,25,26].
The study protocol was registered on PROSPERO database for systematic reviews (Registra-
tion no. CRD42017078607) [27]. The PRISMA Checklist is available as S1 Checklist.
This study was supported by a grant from the Italian Medicines Agency (AIFA–Grant no.
FARM12JFX9). The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Search strategy
Pertinent studies were searched independently in BioMedCentral, PubMed, EMBASE, and the
Cochrane Central Register of clinical trials by four trained investigators (search last updated
October 15th, 2017). The PubMed search strategy used to include any randomized study ever
performed with furosemide in patients with or at risk for AKI [28] is available in S1 Appendix.
In addition, we employed backward snowballing (i.e., scanning of references of retrieved arti-
cles and pertinent reviews) and contacted the international experts and the manufacturers for
further studies. No language restriction was enforced.
Study selection
References, obtained from database and literature searches, were examined first at a title/
abstract level independently by four investigators, with divergences resolved by consensus,
and then, if potentially pertinent, were retrieved as complete articles.
The following inclusion criteria were used for potentially relevant studies: (1) random allo-
cation to treatment, (2) comparison between furosemide bolus versus any comparator, and (3)
critically ill patients. There was no restriction on dose or time of administration. The exclusion
criteria were as follows: (1) non-adult studies, (2) studies with a non-parallel design (e.g., cross-
over) randomized trials, (3) duplicate publications either acknowledged or not (in this case we
referred to the first article published while we retrieved data from the article with the longest
follow-up available, (4) non-human experimental studies, (5) studies with no data on outcome
of interests; and (6) oral furosemide administration.
Two investigators independently assessed the compliance to selection criteria and selected
the studies for the final analysis, with divergences finally resolved by consensus.
Data abstraction and study endpoint
Baseline characteristics, procedural, and outcome data were abstracted independently by four
trained investigators; the divergences were resolved by consensus. Specifically, we extracted
potential sources of significant clinical heterogeneity, such as study design, sample size, clinical
setting/indication, furosemide bolus dose, control treatment, and follow-up duration, as well
as primary study endpoint and other key outcomes. Corresponding author of original authors
were contacted in cases of missing data on outcome of interests.
Furosemide in AKI: A meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0196088 April 24, 2018 3 / 18
Risk of bias assessment
The internal validity and risk of bias of included trials was appraised by two independent
reviewers according to the Risk of Bias Assessment Tool developed by the Cochrane collabora-
tion [29, 30] that assesses the adequacy of randomization sequence generation, the concealment
of treatment allocation, blinding of participating subjects, treating personnel and outcome
assessors, complete reporting of outcome, possible selective outcome reporting, possible other
sources of bias, and provide a final judgement on the overall risk of bias. Publication bias were
assessed by visually inspecting funnel plots for pooled analyses containing>10 studies [31].
Data analysis and synthesis
Computations were performed with RevMan (Review Manager, Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration, 2014; available at http://
community.cochrane.org/tools/review-production-tools/revman-5/revman-5-download).
Hypothesis of statistical heterogeneity was tested by means of Cochran Q test, with statistical
significance set at the two-tailed 0.10 level, whereas extent of statistical consistency was mea-
sured with I2, defined as 100% X (Q-df)/Q, where Q is Cochran’s heterogeneity statistic and
the degrees of freedom (df). Binary outcomes from individual studies were analyzed to com-
pute individual and pooled odds ratio (OR) with pertinent 95% confidence intervals (CIs), fit-
ting a fixed-effect model in case of low statistical inconsistency (I2 <25%) or with random-
effect model (which better accommodates clinical and statistical variations) in case of moder-
ate or high statistical inconsistency (I225%). Weighted mean difference (WMD) and 95%
CIs were computed for continuous variables using the same methods as just described. For
individual studies reporting continuous outcomes as median and range or median and inter-
quartile range, mean and standard deviation were estimated using equations elaborated by
Wan and colleagues [32].
The primary endpoint was all-cause longest follow-up mortality. The pre-specified second-
ary endpoint were 28/30-days mortality, new/worsening AKI, receipt of RRT, length of hospi-
tal stay, and peak serum creatinine after randomization. Outcomes were defined as per-
original author’s definition.
Sensitivity analyses were performed by sequentially removing each study and reanalyzing
the remaining dataset (producing a new analysis for each study removed), by selecting an indi-
vidual subset (defined by setting, control drug, and indication for treatment [e.g., prevention
versus treatment of AKI]), and by analyzing only data from studies with low risk of bias.
Statistical significance was set at the two-tailed 0.05 level for hypothesis testing. Unadjusted
p values are reported throughout.
We performed pre-defined trial sequential analysis (TSA) [33,34], with the intent of main-
taining an overall 5% risk of type I error and a 10% risk of type II error, at a power of 90%. We
assumed a relative risk reduction of 15% for each outcome. The analysis was conducted using
the control event proportion derived from the present meta-analyses. The resulting required
information size was further diversity (D2)-adjusted; in case of D2 = 0, we performed a sensi-
tivity analysis assuming a D2 = 25%. Fixed-effect model was employed. We used the TSA soft-
ware (TSA Viewer [Computer program], version 0.9.5.5 Beta, Copenhagen Trial Unit, Centre
for Clinical Intervention Research, Rigshospitalet, 2016.).
Results
A total of 3632 references were examined. After exclusions of non-pertinent studies, a total of
63 studies were retrieved as complete articles. Of these, 35 were further excluded, as they did
not met inclusion criteria. Details of excluded studies together with reason for exclusion are
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available in the Table A in S1 Appendix. Finally, a total of 28 studies randomizing 3228
patients were included in the analysis (Fig 1) [15–17,22,35–57].
Trials’ characteristics
Characteristics of included trials are described in Table 1. Included trials were performed in
the settings of AKI either in ICU or general ward, cardiac surgery, acutely decompensated
heart failure, and contrast-induced AKI.
In 14 trials control treatment was represented by continuous furosemide infusion, in 12 tri-
als by placebo/standard treatment, and in 2 further trials by an active pharmacological com-
parator. Fifteen trials administered furosemide bolus as a preventive measure in patients who
had not yet developed AKI, while 11 as treatment of established AKI.
Mortality data were available for 19 trials, with four trials reporting 28/30 days mortality. Data
on receipt of RRT were available from 14 trials, data on new onset/worsening AKI from 16 trials,
length of hospital stay in 7 trials and peak serum creatinine following randomization in 6 trials.
Fig 1. Examined studies.
https://doi.org/10.1371/journal.pone.0196088.g001
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Overall, risk of bias analysis showed that none of included trials was at low risk of bias. A
total of 19 trials were considered at high risk of bias, and 9 at unclear risk of bias (Fig 2 and
Figure A in S1 Appendix)
Studies results are reported in the text and in S1 Appendix.
Table 1. Study characteristics.
First author Year Setting Multi center Control treatment N treatment
group
N control
group
Prevention or
treatment?
Ad N [35] 2002 Cardiac surgery No Infusion
furosemide
39 36 Prevention
Allen LA [36] 2010 Acute decompensated heart
failure
No Infusion
furosemide
21 20 Prevention
Bayat F [37] 2015 Cardiac surgery No Standard care 42 42 Prevention
Barbanti M [38] 2015 Contrast-Induced AKI No Standard care 56 56 Prevention
Briguori C [39] 2011 Contrast-Induced AKI Yes Standard care 146 146 Prevention
Brown CB [40] 1981 AKI/ICU No Infusion
furosemide
28 28 Treatment
Cantarovich F [15] 1973 AKI/ICU No Standard care 39 19 Treatment
Copeland JG [41] 1983 Cardiac surgery No Infusion
furosemide
9 9 Prevention
Dussol B [42] 2006 Contrast-Induced AKI No 0.9% Saline 79 77 Prevention
Felker BM [43] 2011 Acute decompensated heart
failure
No Infusion
furosemide
156 152 Prevention
Gu CQ [44] 2013 Contrast-induced AKI Yes Standard care 422 437 Prevention
Karayannopoulos S
[16]
1974 AKI/ICU No Standard care 10 10 Treatment
Kleinknecht D [17] 1976 AKI/ICU No Placebo 33 33 Treatment
Kunt AT [45] 2009 Cardiac surgery No Infusion
furosemide
50 50 Treatment
Llorens P [46] 2014 Acute decompensated heart
failure
No Infusion
furosemide
73 36 Prevention
Marenzi G [47] 2012 Contrast-Induced AKI Yes Standard care 87 83 Prevention
Mojtahedzadeh M [48] 2004 AKI/ICU No Infusion
furosemide
11 11 Prevention
Ostermann M [49] 2007 AKI/ICU No Infusion
furosemide
26 30 Prevention
Palazzuoli A [50] 2014 Acute decompensated heart
failure
No Infusion
furosemide
39 43 Prevention
Schuller D [51] 1997 AKI/ICU No Infusion
furosemide
19 14 Treatment
Shah RA [52] 2014 Acute decompensated heart
failure
No Infusion
furosemide
30 60 Treatment
Shilliday IR [53] 1997 AKI/ICU No Placebo 32 30 Treatment
Solomon R [22] 1994 Contrast-Induced AKI No Saline (± mannitol) 25 53 Prevention
Thomson MR [54] 2010 Acute decompensated heart
failure
No Infusion
furosemide
30 26 Treatment
Usmiani T [55] 2016 Contrast-Induced AKI No Standard care 57 63 Prevention
Vargas Hein O [56] 2005 Cardiac surgery No Torsemide 14 15 Treatment
Yayla C¸ [57] 2015 Acute decompensated heart
failure
No Infusion
furosemide
14 15 Prevention
https://doi.org/10.1371/journal.pone.0196088.t001
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All-cause longest follow-up mortality
Overall, a total of 143/892 (16%) patients assigned to the furosemide bolus group died, as com-
pared with 141/881 (16%) assigned to the control group, with no difference between the two
groups (OR = 0.84; 95% CI 0.63 to 1.13; p-value = 0.25; I2 = 0%) (Table 2) (Figure B in S1
Appendix). Trial sequential analysis was inconclusive with only 25.79% of the information size
accrued, suggesting the need for more randomized controlled trial(s) to establish firm evidence
on the beneficial or detrimental effect on survival of furosemide bolus over control (OR 0.84,
TSA-adjusted 95% CI, 0.46, 1.54) (Figure C in S1 Appendix). In particular, TSA estimated that
the required information size would be 6874 randomized patients to show a 15% relative risk
reduction.
A subgroup effect was identified only for studies administrating furosemide as prevention
versus treatment, with a favorable effect in “prevention” trials (OR = 0.62; 95% CI 0.41 to 0.94;
p-value = 0.03; I2 = 0%, with 9 studies included), and a neutral effect in “treatment” trials
(OR = 1.14; 95% CI 0.75 to 1.72; p-value = 0.54; I2 = 0%, with 9 studies included), with a p-
value between groups = 0.04. (Fig 3). Conversely, a subgroup effect depending on control
treatment or clinical setting was not identified (Figures D and E in S1 Appendix). Trend
towards subgroup differences were identified when stratifying analysis by control treatment
and treatment indication (prevention vs treatment) (Figure D and Table D in S1 Appendix).
Sequentially removing each trial did not change magnitude and direction of treatment
effect (lowest OR = 0.78; 95% CI 0.58 to 1.05; p-value = 0.10; I2 = 0%, removing Kunt et al [45];
highest OR = 0.90; 95% CI = 0.67 to 1.21; p-value = 0.49; I2 = 0%, removing Usmiani et al
[55]).
As no trial with low risk of bias was identified, pre-specified analysis including only low
risk of bias trials was not performed.
Visual inspection of funnel plot did not suggest possible presence of publication bias (Fig 4).
All-cause 28/30-days mortality
Overall, we found no difference in 28/30 days mortality between the treatment and the control
group (16/282 [5.7%] in the furosemide bolus group versus 11/312 [3.5%] in the control
group; OR = 1.62; 95% CI 0.78 to 3.35; p-value = 0.20; I2 = 23%, with 4 studies included) (Fig-
ures F to I in S1 Appendix).
Fig 2. Studies bias.
https://doi.org/10.1371/journal.pone.0196088.g002
Table 2. Overall results.
Analysis Treatment group Control group OR/MD 95% CI p-value for effect p-value for heterogeneity I2 (%)
Longest f-up mortality, n–events/N (%) 143/892 (16%) 141/881 (16%) 0.84 0.63 to 1.13 0.25 0.47 0
28/30 days mortality–events/N (%) 16/282 (8.8%) 11/312 (3.5%) 1.62 0.78 to 3.35 0.20 0.27 23
New/worsening AKI–events/N (%) 179/1335 (13.4%) 243/1333 (18.2%) 0.72 0.47 to 1.10 0.13 0.001 60
Need for RRT–events/N (%) 78/843 (9.3%) 94/842 (11.6%) 0.49 0.21 to 1.15 0.10 0.15 32
Hospital LOS, days–mean ± SD 0.17 -1.04 to 1.39 0.78 0.003 70
Peak serum creatinine, mg/dl 0.10 -0.12 to 0.33 0.36 < 0.001 98
CI: confidence interval; MD: mean difference; OR: odds ratio; AKI: acute kidney injury; RRT: renal replacement therapy; LOS, length of hospital stay.
https://doi.org/10.1371/journal.pone.0196088.t002
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New onset/worsening AKI
Overall, 179/1335 (13.4%) patients assigned to furosemide bolus administration experienced
new onset or worsening of AKI, as compared with 243/1333 (18.2%) patients assigned to the
control group (OR = 0.72; 95% CI = 0.47 to 1.10; p-value = 0.13; I2 = 60%, TSA inconclusive)
(Figure J in S1 Appendix).
A subgroup effect was identified when analyzing trials according to the control treatment, with
a favorable effect of furosemide bolus as compared with placebo/standard treatment and a harm-
ful effect when compared with active pharmacological control (Figures K to M in S1 Appendix).
Receipt of RRT
Overall, 78/843 (9.3%) patients assigned to furosemide bolus administration received RRT, as
compared with 94/842 (11.6%) patients assigned to the control group (OR = 0.49; 95%
CI = 0.21 to 1.15; p-value = 0.10; I2 = 32%, TSA inconclusive) (Figure N in S1 Appendix).
A trend towards a subgroup effect was identified when analyzing trials according to setting,
with a favorable effect of furosemide bolus in the setting of contrast-induced AKI and a trend
towards a harmful effect in cardiac surgery (Figure P in S1 Appendix). In addition, in the
Fig 3. Furosemide prevention VS treatment subgroup.
https://doi.org/10.1371/journal.pone.0196088.g003
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subgroup of patients receiving preventive furosemide administration, we observed a signifi-
cant reduction in receipt of RRT (Figure Q in S1 Appendix).
Length of hospital stay
Pooled analysis of the 6 trials that reported hospital length of stay did not show a statistically
significant difference between furosemide bolus and control treatment (WMD = 0.17; 95%
CI = -1.04 to 1.39; p-value = 0.78; I2 = 70%) (Figure R in S1 Appendix). A trend towards a
subgroup difference was identified when comparing trials administering furosemide as a
preventive measure as compared with trials administering it as treatment (Figures S to U in
S1 Appendix).
Peak serum creatinine
Pooled analysis of the 6 trials reporting peak serum creatinine after randomization did not
show a statistically significant difference between furosemide bolus and control treatment
(WMD = 0.10; 95% CI = -0.12 to 0.33; p-value = 0.36; I2 = 98%) (Figure V in S1 Appendix). A
subgroup effect was identified when analyzing trials according to the setting, with trials per-
formed in cardiac surgery setting showing an increase in serum creatinine associated with
bolus furosemide administration (Figures V to Y in S1 Appendix).
Fig 4. Funnel plot.
https://doi.org/10.1371/journal.pone.0196088.g004
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Contrast-induced AKI
Subgroup analyses comparing trials performed in the setting of contrast-induced AKI versus
trials performed in all other settings did not identify a subgroup effect except in any of the ana-
lysed outcomes with the exception of all-cause 28/30-days mortality (p for interaction = 0.04)
(Figures AB to AF in S1 Appendix).
Discussion
Key findings
In this meta-analysis of RCTs, we found that intermittent furosemide administration in
patients with or at risk for AKI did not result in a lower mortality, reduced incidence or wors-
ening of AKI, or decreased utilization of RRT. A trend towards a beneficial effect of intermit-
tent furosemide administration was found when analyzing the subgroup of studies in which
furosemide was administered to prevent AKI. This finding was consistent across different out-
comes, with a similar beneficial effect on RRT utilization and a trend towards a beneficial effect
on worsening AKI, length of hospital stay, and peak serum creatinine in “prevention” trials.
However, TSA was inconclusive, suggesting no firm conclusions on the topic and the need of
further high-quality studies on the topic.
Relationship to previous studies
The effect of loop diuretics on incidence and course of AKI has been a matter of debate and
investigation for years. Accordingly, several RCTs and observational trials have been per-
formed investigating the effect of diuretics and optimal diuretic strategy. As of today, convinc-
ing evidence that diuretic administration can alter per se the course of AKI or shorten renal
recovery when RRT is needed is lacking [4,58,59].
In the largest meta-analysis performed so far on furosemide administration in patients with
or at risk for AKI, the authors included a total of 11 studies and found no difference in mortal-
ity or RRT utilization between the furosemide and control group, for both AKI prevention and
treatment [60]. Compared with this study, our meta-analysis specifically investigated the role
of intermittent furosemide administration versus any comparator, including continuous furo-
semide infusion. In addition, we included a larger number of trials and patients, including
some recent, large multicenter RCTs [42,46].
Other meta-analyses on the role of loop diuretics in prevention or treatment of AKI in dif-
ferent settings and with different inclusion criteria have been performed [61,62,63,64], all of
which consistently found that loops diuretics administration was not associated with improved
outcome in patients with AKI. Meta-analyses consistently confirmed a higher urine output
associated with diuretics use [62,63] and some suggested a possible shorter duration of RRT
[62] and number of dialysis treatments [63], although level of evidence was considered to be
low. A positive effect of furosemide administration on RRT use was confirmed in our study,
although limited to trials investigating preventive role of furosemide. Conversely, meta-analy-
ses and small trials questioned the beneficial effect of furosemide on incidence or clinical
course of AKI [37,61,65]. To clarify these issues, a pilot multicenter RCT on continuous furo-
semide administration versus placebo in critically ill patients with AKI (the SPARK study) was
planned [66]. The study aimed at enrolling 216 patients with early AKI defined according to
R-RIFLE criteria [67], with worsening AKI as primary endpoint. Unfortunately, the trial was
interrupted early due to logistic problems and lack of funding after only 73 patients had been
enrolled, and found no difference in the primary or any of secondary outcomes [68]. However,
furosemide administration was associated with a higher risk of electrolyte abnormalities.
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Several meta-analyses compared continuous versus intermittent furosemide administration
in patients several clinical settings, both in adults and pediatric patients [69,70,71,72]. This
meta-analyses yielded small differences in results depending on trial inclusion criteria, but
consistently confirmed no improvement in major outcomes associated with any of the two
strategies. The largest meta-analysis, including all RCTs performed on hospitalized patients
(including pediatric and crossover studies), suggested that continuous administration might
be associated with greater urine output [72], especially when preceded by a single bolus.
Whether this translates in improved clinical outcome remains to be determined [73]. Com-
pared with previously published meta-analyses, we focused on adult patients only and included
a larger number of trials and comparators, while excluding crossover studies, as our meta-anal-
ysis aimed at investigating clinically relevant outcomes such as mortality.
Significance of study findings
Our study suggested that furosemide administration may have some benefits when used to pre-
vent AKI, both in terms of mortality and need for RRT. However, we believe that our results
should be interpreted with caution, as also suggested by TSA that was inconclusive due to too
low information size. Indeed, positive results observed with furosemide administration are
largely driven by trials performed in the setting of CI-AKI, and in particular by four trials investi-
gating an automated fluid delivery system (RenalGuard, PLC Medical Systems, Milford, Massa-
chusetts) which matches hydration with diuresis [41,42,50,58]. In these studies, furosemide
administration to maintain a diuresis 300 mL/h with matched hydration was shown to prevent
CI-AKI and subsequent need for RRT without major adverse events related to fluid overload
[74]. Notably, volume expansion is currently the only widely recommended strategy to prevent
CI-AKI [75,76] while furosemide was shown to have detrimental effect when not coupled with
adequate hydration [22,23,45,77]. Accordingly, beneficial effect of RenalGuard system is proba-
bly related not on furosemide administration, but on the adequate diuresis achieved together
with targeted volume expansion, thus limiting the risk of both fluid overload and dehydration.
To further complicate the picture, published RCTs on RenalGuard system were all considered to
be at high risk of bias, thereby downgrading level of evidence of this strategy [74], while the effec-
tiveness of volume expansion in preventing CI-AKI has been recently challenged [78].
The role of fluid overload on incidence and pathogenesis of AKI and organ dysfunction in
critically ill and surgical patients has been largely investigated in recent years [19,79,80,81]. It
is now generally recognized that also excessive fluid overload and high central venous pressure
causes renal congestion and impaired kidney perfusion, both in heart failure and critically ill
patients. In this context, positive effects observed with furosemide administration in patients
with AKI may be related to an indirect mechanism mediated by fluid removal, rather than a
direct positive effect of loop diuretics. Accordingly, recent guidelines recommend diuretics use
to optimize patient volume status [4,35]. A major problem in fluid management in patients
with AKI is that both hypovolemia and hypervolemia are associated with AKI development
and progression [79,80]. As a consequence, the same diuretic that might improve renal func-
tion in fluid-overloaded patient may have detrimental effect on kidney perfusion if a patient is
or become volume-depleted. This dual effect can explain the controversial results obtained so
far by studies investigating the role of diuretics in prevention or treatment of AKI.
It is a common clinical observation that reversal of oligo-anuria with furosemide adminis-
tration is frequently associated with improvement in renal function. A furosemide stress test
to assess AKI severity and likelihood of progression has been recently developed and validated
[82,83]. Chawla et al. showed that a diuresis of at least 200 mL in two hours following a 1–1.5
mg/kg furosemide bolus was associated with reduced AKI progression. This might occur
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because adequate diuretic response to furosemide required adequate renal perfusion, active
secretion of the drug in the tubule, and absence of urinary flow obstruction, all indicative of
less severe injury and adequate renal reserve. Thereby, this simple test could globally evaluate
kidney function and renal reserve. Therefore, in clinical practice, reversal of oligo-anuria with
furosemide is more likely a marker of reduced kidney injury and/or dysfunction, rather than
of a beneficial effect exerted by furosemide.
Limitations of the study
Our study has some limitations, which are characteristics of all aggregate data meta-analyses
[24,84]. First, we included several studies performed in different setting, with different aims and
different control groups. However, we also performed several subgroup analyses, which helped
us to better define the influence of each subgroup on overall results. Second, all of the included
trials were considered to carry an unclear or a high risk of bias, thereby reducing quality of evi-
dence that our meta-analysis can provide. Nevertheless, identifying lack of high-quality trials
and gaps in evidence on a topic is also an objective of systematic reviews and meta-analyses. In
a similar context, meta-analyses should be considered hypothesis-generating rather than confir-
matory. Third, some of the included studies were performed decades ago. Finally, we focused
on adult patients receiving intermittent furosemide administration. Therefore, our results may
not apply to continuous furosemide administration or pediatric population, although previous
meta-analyses did not suggest that a different effect in this setting is expected.
Future studies and prospects
The role of furosemide and, diuretics administration in patients with or at risk for AKI still
needs to be clearly determined. While it is generally accepted that available diuretics are
unlikely to exert a direct kidney-protective effect in real-world clinical practice, an indirect
effect through optimization of volume status can not be excluded. Future trials should better
address this issue. An ideal trial should investigate whether optimization of volume status with
diuretics reduces AKI development or progression. However, such a study is unlikely to be
conducted mainly due to organizing and ethical reasons. Alternatively, it may be interesting to
compare a diuretic-based versus an early-RRT-based fluid management strategy in AKI.
Conclusions
Randomized trials showed that intermittent furosemide administration is not associated with
an overall improvement in survival or other major outcomes in patients with or at risk for
AKI, although it may reduce mortality and RRT utilization when used as a preventive measure.
However, these findings are largely influenced by a specific subset of trials performed in
CI-AKI setting and likely attributable to the concomitant management protocol investigated
in these trials. Furthermore, low risk of bias trials are lacking. Future high quality trials are
needed to confirm the role of loop diuretics in AKI prevention and management, although
ethical issues may limit feasibility.
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